Qube Research & Technologies LTD Tempest Therapeutics, Inc. Transaction History
Qube Research & Technologies LTD
- $62.3 Billion
- Q2 2024
A detailed history of Qube Research & Technologies LTD transactions in Tempest Therapeutics, Inc. stock. As of the latest transaction made, Qube Research & Technologies LTD holds 27 shares of TPST stock, worth $39. This represents 0.0% of its overall portfolio holdings.
Number of Shares
27
Previous 27
-0.0%
Holding current value
$39
Previous $0
NaN%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding TPST
# of Institutions
28Shares Held
1.72MCall Options Held
30KPut Options Held
80.5K-
Black Rock Inc. New York, NY550KShares$808,8540.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA176KShares$259,0030.0% of portfolio
-
Geode Capital Management, LLC Boston, MA154KShares$226,7340.0% of portfolio
-
Fil LTD Hamilton, D0130KShares$190,4810.0% of portfolio
-
Ikarian Capital, LLC Dallas, TX106KShares$155,2320.09% of portfolio
About Tempest Therapeutics, Inc.
- Ticker TPST
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 10,418,900
- Market Cap $15.3M
- Description
- Tempest Therapeutics Inc., a clinical-stage oncology company, engages in developing small molecule therapeutics to treat cancer. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, and is currently in a Phase 1 trial in solid tumors; and TPST-1120, a selective antagonist of peroxiso...